GlassScriptPhysician profile
Maria Isabel Hernandez
NPI 1356583629
$2,428.36
in general payments reported to CMS, 2019-2025
25 companies · $43.36 in 2025
The $43.36 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $659 · 2022: $943 · 2023: $559 · 2024: $224 · 2025: $43.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $671.93 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Ucb, INC. | $500.15 | 2021-2022 | |
| Novo Nordisk INC | $150.48 | 2021-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $140.58 | 2021-2023 | |
| Astellas Pharma US INC | $116.40 | 2021-2024 | Veozah |
| Abbvie INC. | $103.83 | 2022 | |
| Abbott Laboratories | $101.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.52 | 2022-2023 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $64.17 | 2021-2023 | Trelegy Ellipta |
| Boston Scientific Corporation | $60.22 | 2021 | |
| Pfizer INC. | $49.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.05 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $44.45 | 2021 | |
| Exact Sciences Corporation | $41.59 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $40.57 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $35.05 | 2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $28.19 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $27.35 | 2021-2024 | Airsupra |
| Genentech USA, INC. | $22.23 | 2025 | Tecentriq Hybreza |
| E.R. Squibb & Sons, L.L.C. | $21.13 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $19.50 | 2022 | |
| Antares Pharma, INC. | $17.90 | 2024 | Xyosted |
| Angiodynamics, INC. | $17.04 | 2021 | |
| Dexcom, INC. | $15.72 | 2021 | |
| Amarin Pharma, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.